
News|Articles|May 27, 2026
The Current State of DEI in Clinical Trials: Progress, Pressure, and the Path Forward
Author(s)Andy Studna, Senior Editor
Despite political headwinds, life sciences leaders are holding their ground on DEI, but translating organizational commitment into representative enrollment requires structural changes to protocol design, site selection, and community engagement that most of the industry has yet to fully make.
Advertisement
Advertisement
The industry has been discussing clinical trial diversity, equity, and inclusion (DEI) for decades. What is different now is the convergence of regulatory expectations, organizational accountability structures, and a political environment that is simultaneously creating pressure and hesitancy. Understanding where progress is real, where it is stalling, and what is actually working is more important than ever.
Related to this article

Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.

In this Q&A, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, discusses why so many patients from underrepresented groups are never asked to join a clinical trial, how AI-enabled matching and screening can make oncology access more consistent, and why the conversation with the patient must stay human.

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.

Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.

Participants in a survey of 354 pre-screening respondents rated AI voice-assisted screening (Clara) favorably and were more likely to schedule and attend study appointments than web-form users, though self-selection means the association cannot be read as causal.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, describes how physician awareness and site-level access drive screening inconsistencies, and why acceptance rates are the same across backgrounds once patients are simply asked.

Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
Advertisement
Advertisement

